NSE ScannerNippon India Mutual Fund · Equity · Sectoral / Thematic · Direct plan
Nippon India Pharma Fund - Direct Plan - Growth
₹625.4566NAV on 30 Oct 2026Expense ratio 1.00%
29 Oct 2025NAV low 539.27 · high 653.61+8.6%
In plain words
Over 3 years it returned +18.6% a year, against +7.4% for its benchmark index.
Its worst fall from a peak in the last 3 years was -14.7%.
On 3-year return it ranks 36 of 138 funds in Sectoral / Thematic.
A monthly SIP over 10 years ended ₹1,71,941 higher in the direct plan than the regular plan, because of the lower expense ratio.
Past returns, not a promise of future returns or a recommendation.
Returns vs benchmark
| Period | Fund | Benchmark |
|---|---|---|
| 1 month | -0.8% | +1.9% |
| 3 months | -2.5% | -5.1% |
| 6 months | +7.8% | -3.2% |
| 1 year | +9.1% | -10.2% |
| 3 years (yearly) | +18.6% | +7.4% |
| 5 years (yearly) | +14.2% | +6.5% |
| 10 years (yearly) | +15.2% | +11.3% |
| Since start (yearly) | +17.2% | +11.2% |
Monthly SIP of ₹10,000
| Period | Invested | Value now | Yearly return |
|---|---|---|---|
| 1 year | ₹1,20,000 | ₹1,27,952 | +11.0% |
| 3 years | ₹3,60,000 | ₹4,27,423 | +10.9% |
| 5 years | ₹5,90,000 | ₹8,85,583 | +16.1% |
| 10 years | ₹11,90,000 | ₹30,91,709 | +18.1% |
Top holdings (30 Sept 2026)
Fund size ₹9,166 crore · 36 holdings · 97.3% in equity
| Company | Industry | Weight |
|---|---|---|
| Sun Pharmaceutical Industries Limited | Pharmaceuticals & Biotechnology | 11.71% |
| Divi's Laboratories Limited | Pharmaceuticals & Biotechnology | 7.10% |
| Lupin Limited | Pharmaceuticals & Biotechnology | 6.17% |
| Cipla Limited | Pharmaceuticals & Biotechnology | 6.01% |
| Dr. Reddy's Laboratories Limited | Pharmaceuticals & Biotechnology | 5.45% |
| Apollo Hospitals Enterprise Limited | Healthcare Services | 4.89% |
| Mankind Pharma Limited | Pharmaceuticals & Biotechnology | 4.38% |
| Sai Life Sciences Limited | Pharmaceuticals & Biotechnology | 3.92% |
| Ajanta Pharma Limited | Pharmaceuticals & Biotechnology | 3.61% |
| GlaxoSmithKline Pharmaceuticals Limited | Pharmaceuticals & Biotechnology | 3.11% |
| IPCA Laboratories Limited | Pharmaceuticals & Biotechnology | 2.87% |
| Max Healthcare Institute Limited | Healthcare Services | 2.70% |
| Vijaya Diagnostic Centre Limited | Healthcare Services | 2.62% |
| Gland Pharma Limited | Pharmaceuticals & Biotechnology | 2.53% |
| MedPlus Health Services Limited | Retailing | 2.53% |
Largest industries: Pharmaceuticals & Biotechnology 74.0%, Healthcare Services 20.3%, Retailing 2.5%, Healthcare Equipment & Supplies 0.5%.
Other plan of this fund: Nippon India Pharma Fund - Regular Plan - Growth